Medexus Pharmaceuticals (MDP.T) is a Canadian specialty pharma company servicing the North American market. The company has developed a robust portfolio of orphan drugs that continues to grow revenue, yet the stock market has completely missed the point.
Equity Guru founder, Chris Parry, dives into Medexus’ financials and discusses the disconnect between the company’s revenues and its market cap where Medexus is valued at one-quarter of the money it brings in the door. With new drugs continuing to join the company’s pipeline and ongoing growth of its existing drug offerings, there is a unique potential for investors.
Is it time to give Medexus consideration? Find out here.